← GLP-1 receptor agonists × glycemic control

TrialThe Journal of clinical endocrinology and metabolism2018

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

Helena W Rodbard et al.PubMed ↗Full text ↗Publisher ↗

  • Semaglutide 0.5 mglooks good hereLower HbA1c reduction from baseline to week 30, lower body weight decrease from baseline to end of treatment, no clear effect on severe or blood glucose-confirmed hypoglycemic episodes.Randomised, small.
  • Semaglutide 1.0 mglooks good hereLower HbA1c reduction from baseline to week 30, lower body weight decrease from baseline to end of treatment, no clear effect on severe or blood glucose-confirmed hypoglycemic episodes.Randomised, small.

What the trial testedrandomised · 397 people · 2018

Randomised vs placebo

Probably lowered HbA1c reduction from baseline to week 30

−1.35−1.61 to −1.10

semaglutide 0.5 mg vs placebo

As reported

difference −1.35, 95% CI −1.61 to −1.10

Randomised vs placebo

Probably lowered HbA1c reduction from baseline to week 30

−1.75percentage points−2.01 to −1.50

semaglutide 1.0 mg vs placebo

As reported

difference −1.75 %, 95% CI −2.01 to −1.50

Randomised vs placebo

Probably lowered body weight decrease from baseline to end of treatment

−2.31−3.33 to −1.29

semaglutide 0.5 mg vs placebo

As reported

difference −2.31, 95% CI −3.33 to −1.29 · the paper's word: Mean body weight decrease from baseline to end of treatment

Randomised vs placebo

Probably lowered body weight decrease from baseline to end of treatment

−5.06−6.08 to −4.04

semaglutide 1.0 mg vs placebo

As reported

difference −5.06, 95% CI −6.08 to −4.04 · the paper's word: Mean body weight decrease from baseline to end of treatment

+2 more in the walkthrough ↓

Who was studied, and how

397people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

semaglutide 0.5 mg
placebo

Probably lowered HbA1c reduction from baseline to week 30−1.35

Probably lowered body weight decrease from baseline to end of treatment−2.31

No clear effect on severe or blood glucose-confirmed hypoglycemic episodes2.1×

randomised

The trial randomly assignedassigned by chance

semaglutide 1.0 mg
placebo

Probably lowered HbA1c reduction from baseline to week 30−1.75

Probably lowered body weight decrease from baseline to end of treatment−5.06

No clear effect on severe or blood glucose-confirmed hypoglycemic episodes2.4×

randomised

the abstract, start to end

… treatment difference (ETD) vs placebo, -1.35 (14.8 mmol/mol); 95% CI, -1.61 to -1.10 and ETD, -1.75% (19.2 mmol/mol); 95% CI, -2.01 …

… (estimated rate ratio vs placebo, 2.08; 95% CI, 0.67 to 6.51 and estimated rate ratio vs placebo, 2.41; 95% CI, 0.84 to 6.96 for 0.5 …

… of treatment: 3.7, 6.4, and 1.4 kg (ETD, -2.31; 95% CI, -3.33 to -1.29 and ETD, -5.06; 95% CI, -6.08 to -4.04 kg; …

← favours treatmentfavours comparator →
could be chance
HbA1c reduction from baseline to week 30semaglutide 0.5 mg vs placebo
−1.35−1.61 to −1.10
HbA1c reduction from baseline to week 30semaglutide 1.0 mg vs placebo
−1.75−2.01 to −1.50
Severe or blood glucose-confirmed hypoglycemic episodessemaglutide 0.5 mg vs placebo
IRR 2.080.67–6.51
Severe or blood glucose-confirmed hypoglycemic episodessemaglutide 1.0 mg vs placebo
IRR 2.410.84–6.96
Mean body weight decrease from baseline to end of treatmentsemaglutide 0.5 mg vs placebo
−2.31−3.33 to −1.29
Mean body weight decrease from baseline to end of treatmentsemaglutide 1.0 mg vs placebo
−5.06−6.08 to −4.04
GLP-1 receptor agonistsGlycemic controlBody weight & compositionHypoglycaemia

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it

GLP-1 receptor agonists × hypoglycaemiaharms?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this paperthis papermore certainless certain
1 / 6

182 papers cite itlatest 60 shown

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT02305381phase 3397 enrolled2014
Full record →Abstract, authors, funding and every citing paper · PMID 29688502